Medicus Pharma Ltd. 8-K filed 2026-09-11

Medicus Pharma Ltd., which trades on Nasdaq under the tickers MDCX and MDCXW and files under SIC code 2834 (Pharmaceutical Preparations), filed this 8-K on 2026-09-11 to report an unregistered sale of equity securities under Item 3.02. On September 4, 2026, the company awarded cash bonuses in the aggregate amount of approximately $1.45 million to certain officers and employees. Each recipient elected to forgo the cash payment and take the value of the bonus in restricted common shares instead. Under those elections, the company granted an aggregate of 8,529,412 restricted Common Shares. Each recipient's share count was set by dividing the forgone bonus by $0.1705 per share, which the filing identifies as the closing price of the Common Shares on the Nasdaq Capital Market on September 3, 2026. The filing states that no additional consideration was paid to, or received by, the company in connection with the issuance. The company relied on the Section 4(a)(2) exemption from registration under the Securities Act of 1933, as a transaction by an issuer not involving a public offering. For an analyst or journalist, the filing records new equity issued to insiders in place of cash compensation, priced off a single day's closing share price of $0.1705. The report is signed by Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer, and the company is listed as an emerging growth company. Several details a reader would want are not in the filing. These include the names of the individual officers and employees, the bonus and share amounts for each recipient, the vesting or restriction terms on the shares, the company's total shares outstanding before or after the grant, and the reasons the bonuses were awarded. The only exhibit listed is Exhibit 104, the cover page interactive data file.